81 Matching Annotations
  1. Last 7 days
  2. Jul 2021
  3. Jun 2021
    1. Borobia, A. M., Carcas, A. J., Pérez-Olmeda, M., Castaño, L., Bertran, M. J., García-Pérez, J., Campins, M., Portolés, A., González-Pérez, M., García Morales, M. T., Arana-Arri, E., Aldea, M., Díez-Fuertes, F., Fuentes, I., Ascaso, A., Lora, D., Imaz-Ayo, N., Barón-Mira, L. E., Agustí, A., … Torvisco, J. M. (2021). Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): A multicentre, open-label, randomised, controlled, phase 2 trial. The Lancet, S0140673621014203. https://doi.org/10.1016/S0140-6736(21)01420-3

    1. Regev-Yochay, G., Amit, S., Bergwerk, M., Lipsitch, M., Leshem, E., Kahn, R., Lustig, Y., Cohen, C., Doolman, R., Ziv, A., Novikov, I., Rubin, C., Gimpelevich, I., Huppert, A., Rahav, G., Afek, A., & Kreiss, Y. (2021). Decreased Infectivity Following BNT162b2 Vaccination. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3815668

    1. Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A., Lutrick, K., Kuntz, J. L., Dunnigan, K., Odean, M. J., Hegmann, K. T., Stefanski, E., Edwards, L. J., Schaefer-Solle, N., Grant, L., Ellingson, K., … Gaglani, M. (2021). Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers—Eight U.S. Locations, December 2020–March 2021. MMWR. Morbidity and Mortality Weekly Report, 70(13), 495–500. https://doi.org/10.15585/mmwr.mm7013e3

    1. Hall, V. J., Foulkes, S., Saei, A., Andrews, N., Oguti, B., Charlett, A., Wellington, E., Stowe, J., Gillson, N., Atti, A., Islam, J., Karagiannis, I., Munro, K., Khawam, J., Group, T. S. S., Chand, M. A., Brown, C., Ramsay, M. E., Bernal, J. L., & Hopkins, S. (2021). Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study) (SSRN Scholarly Paper ID 3790399). Social Science Research Network. https://doi.org/10.2139/ssrn.3790399

  4. May 2021
    1. Eric Topol. (2021, May 1). Downgrading the concern on B.1.617, the poorly named ‘double mutant’—98% effectiveness of mRNA vaccine in an Israeli outbreak @CT_Bergstrom https://t.co/tGbuwPUmAL —Lab studies: Minimal immune evasion, expected full protection from vaccine @GuptaR_lab https://t.co/AIp24G0ROK https://t.co/AK20UWlDBD [Tweet]. @EricTopol. https://twitter.com/EricTopol/status/1388539223230140422

    1. Adam Kucharski. (2021, April 14). If populations are highly vaccinated, we’d expect a higher proportion of future cases to have been previously vaccinated (because by definition, there aren’t as many non-vaccinated people around to be infected). But what sort of numbers should we expect? A short thread... 1/ [Tweet]. @AdamJKucharski. https://twitter.com/AdamJKucharski/status/1382242089673617417

    1. Hall, V. J., Foulkes, S., Saei, A., Andrews, N., Oguti, B., Charlett, A., Wellington, E., Stowe, J., Gillson, N., Atti, A., Islam, J., Karagiannis, I., Munro, K., Khawam, J., Chand, M. A., Brown, C. S., Ramsay, M., Lopez-Bernal, J., Hopkins, S., … Heeney, J. L. (2021). COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): A prospective, multicentre, cohort study. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(21)00790-X

  5. Apr 2021
    1. Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., Caspi, I., Levy, R., Leschinsky, M., Dror, S. K., Bergerzon, G., Gadban, H., Gadban, F., Eliassian, E., Shimron, O., Saleh, L., Ben-Zvi, H., Amichay, D., Ben-Dor, A., … Stern, A. (2021). Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals. MedRxiv, 2021.04.06.21254882. https://doi.org/10.1101/2021.04.06.21254882

  6. Mar 2021
  7. Feb 2021
    1. Verani, J. R., Baqui, A. H., Broome, C. V., Cherian, T., Cohen, C., Farrar, J. L., Feikin, D. R., Groome, M. J., Hajjeh, R. A., Johnson, H. L., Madhi, S. A., Mulholland, K., O’Brien, K. L., Parashar, U. D., Patel, M. M., Rodrigues, L. C., Santosham, M., Scott, J. A., Smith, P. G., … Zell, E. R. (2017). Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls. Vaccine, 35(25), 3295–3302. https://doi.org/10.1016/j.vaccine.2017.04.037

    1. Shen, X., Tang, H., McDanal, C., Wagh, K., Fischer, W. M., Theiler, J., Yoon, H., Li, D., Haynes, B. F., Saunders, K. O., Gnanakaran, S., Hengartner, N. W., Pajon, R., Smith, G., Dubovsky, F., Glenn, G. M., Korber, B. T., & Montefiori, D. C. (2021). SARS-CoV-2 Variant B.1.1.7 is Susceptible to Neutralizing Antibodies Elicited by Ancestral Spike Vaccines (SSRN Scholarly Paper ID 3777473). Social Science Research Network. https://papers.ssrn.com/abstract=3777473

  8. Jan 2021
    1. ReconfigBehSci. (2020, November 9). RT @peterbachmd: Relevant today: Ever sharp @nataliexdean on Vaccine Effectiveness vs Efficacy from many moons ago (i.e. About a month). Sh… [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1325889181097267200

  9. Dec 2020
  10. Oct 2020
  11. Sep 2020
    1. Natalie E. Dean en Twitter: “VACCINE EFFICACY 101: A biostatistician's primer. Ten tweets to cover:- How is vaccine efficacy calculated?- Distinguishing between infection, disease, & severe disease.- Measuring reduced infectiousness.- Vaccine efficacy vs. effectiveness!n” / Twitter. (n.d.). Twitter. Retrieved September 30, 2020, from https://twitter.com/nataliexdean/status/1310613702476017666

  12. Jul 2020
  13. Jun 2020